This clinical trial examines a palliative care intervention called patient-centered, optimal integration of survivorship and palliative care (POISE) in improving quality of life in patients with non-small cell lung cancer that has spread to other places in the body (metastatic). Patients with lung cancer receiving targeted therapy may experience uncertainty and distress. Early integration of palliative and oncology care may improve patients’ quality of life, coping, illness understanding, and communication. The POISE intervention may decrease distress related to prognostic uncertainty, increase self-efficacy for managing chronic disease, improve prognostic awareness, and increase communication about goals and values in patients with non-small cell lung cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT04900935.
Locations matching your search criteria
United States
Massachusetts
Boston
Massachusetts General Hospital Cancer CenterStatus: Active
Contact: Laura Anne Petrillo
Phone: 617-724-4000
PRIMARY OBJECTIVE:
I. To refine and pilot test a brief, population-specific palliative care intervention for patients with metastatic oncogene-driven non-small cell lung cancer (NSCLC).
II. Test the feasibility and acceptability of the intervention, as well as the preliminary efficacy of the intervention in improving emotional coping with prognosis, increasing patient self-efficacy for managing chronic disease, improving prognostic awareness, and increasing documentation of communication about goals and values. (Randomized Control Trial Phase)
OUTLINE:
STAKE HOLDER INPUT PHASE: Participants complete a semi-structured interview on study.
PILOT STUDY PHASE: Patients meet with palliative care clinician over 60 minutes every 4 weeks for 4 visits. Participants also completion questionnaires at baseline and 12 and 20 weeks after enrollment and participate in an exit interview. Patients' medical records are also reviewed.
RANDOMIZED CONTROLLED TRIAL PHASE: Patients are randomized to 1 of 2 arms.
ARM I (POISE): Patients meet with palliative care clinician over 60 minutes every 4 weeks for 4 visits. Patients also completion questionnaires at baseline and 12 and 20 weeks after enrollment.
ARM II (Usual Care): Patients receive standard oncology care, including specialist palliative care or other support services per the clinical discretion of the oncology team. Patients also completion questionnaires at baseline and 12 and 20 weeks after enrollment.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorLaura Anne Petrillo
